Structure‐Based Approaches to Target Fishing and Ligand Profiling

Chemogenomics is an emerging interdisciplinary field aiming at identifying all possible ligands of all possible targets. If one groups targets in columns and ligands in rows, chemogenomic approaches to drug discovery just fill the interaction matrix. Since experimental data do not suffice, several computational methods are currently actively developed to supplement time‐consuming and costly experiments. They are either designed to fill rows and thus profile a ligand towards a heterogeneous set of targets (target profiling) or to fill columns and thus identify novel ligands for an existing target (standard virtual screening). At the interface of both strategies are now true chemogenomic computational methods filling well defined areas in the matrix. The present review will focus on (protein) structure‐based approaches and illustrates major advances in this novel exciting field which is supposed to massively impact rational drug design in the next decade.

[1]  Ruben Abagyan,et al.  Nuclear hormone receptor targeted virtual screening. , 2003, Journal of medicinal chemistry.

[2]  H. Wolfson,et al.  Recognition of Functional Sites in Protein Structures☆ , 2004, Journal of Molecular Biology.

[3]  Didier Rognan,et al.  sc-PDB: an Annotated Database of Druggable Binding Sites from the Protein Data Bank , 2006, J. Chem. Inf. Model..

[4]  G. Klebe,et al.  Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. , 2004, Journal of medicinal chemistry.

[5]  Lei Xie,et al.  Detecting evolutionary relationships across existing fold space, using sequence order-independent profile–profile alignments , 2008, Proceedings of the National Academy of Sciences.

[6]  Jian Wang,et al.  In Silico Elucidation of the Molecular Mechanism Defining the Adverse Effect of Selective Estrogen Receptor Modulators , 2007, PLoS Comput. Biol..

[7]  S. Ekins,et al.  In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling , 2007, British journal of pharmacology.

[8]  Satoshi Niijima,et al.  GLIDA: GPCR—ligand database for chemical genomics drug discovery—database and tools update , 2007, Nucleic Acids Res..

[9]  Irini Akritopoulou-Zanze,et al.  Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors. , 2009, Drug discovery today.

[10]  Adrian H Elcock,et al.  Progress toward virtual screening for drug side effects , 2002, Proteins.

[11]  Jing Chen,et al.  Pocket v.2: Further Developments on Receptor-Based Pharmacophore Modeling , 2006, J. Chem. Inf. Model..

[12]  G. Schneider,et al.  PocketPicker: analysis of ligand binding-sites with shape descriptors , 2007, Chemistry Central Journal.

[13]  Philip E. Bourne,et al.  A robust and efficient algorithm for the shape description of protein structures and its application in predicting ligand binding sites , 2007, BMC Bioinformatics.

[14]  Jean-Philippe Vert,et al.  Virtual screening of GPCRs: An in silico chemogenomics approach , 2008, BMC Bioinformatics.

[15]  Scott Boyer,et al.  Ligand-Based Approach to In Silico Pharmacology: Nuclear Receptor Profiling , 2006, J. Chem. Inf. Model..

[16]  Ajay N. Jain,et al.  Robust ligand-based modeling of the biological targets of known drugs. , 2006, Journal of medicinal chemistry.

[17]  C. E. Peishoff,et al.  A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.

[18]  Andreas Bender,et al.  "Bayes Affinity Fingerprints" Improve Retrieval Rates in Virtual Screening and Define Orthogonal Bioactivity Space: When Are Multitarget Drugs a Feasible Concept? , 2006, J. Chem. Inf. Model..

[19]  Philip E. Bourne,et al.  Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis , 2009, PLoS Comput. Biol..

[20]  Xiaomin Luo,et al.  PDTD: a web-accessible protein database for drug target identification , 2008, BMC Bioinformatics.

[21]  J M Blaney,et al.  A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.

[22]  Jordi Mestres,et al.  SHED: Shannon Entropy Descriptors from Topological Feature Distributions , 2006, J. Chem. Inf. Model..

[23]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[24]  Thierry Langer,et al.  Molecule-pharmacophore superpositioning and pattern matching in computational drug design. , 2008, Drug discovery today.

[25]  Valentin A. Ilyin,et al.  LigBase: a database of families of aligned ligand binding sites in known protein sequences and structures , 2002, Bioinform..

[26]  Didier Rognan,et al.  Customizing G Protein-coupled receptor models for structure-based virtual screening. , 2009, Current pharmaceutical design.

[27]  David A. Gough,et al.  Virtual Screen for Ligands of Orphan G Protein-Coupled Receptors , 2005, J. Chem. Inf. Model..

[28]  Y.Z. Chen,et al.  Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule , 2001, Proteins.

[29]  G. Klebe,et al.  A new method to detect related function among proteins independent of sequence and fold homology. , 2002, Journal of molecular biology.

[30]  Anne Mai Wassermann,et al.  Ligand Prediction for Orphan Targets Using Support Vector Machines and Various Target-Ligand Kernels Is Dominated by Nearest Neighbor Effects , 2009, J. Chem. Inf. Model..

[31]  Gilles Marcou,et al.  Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints , 2007, J. Chem. Inf. Model..

[32]  Christopher R. Corbeil,et al.  Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go , 2008, British journal of pharmacology.

[33]  Jarl E. S. Wikberg,et al.  Interaction Model Based on Local Protein Substructures Generalizes to the Entire Structural Enzyme-Ligand Space , 2008, J. Chem. Inf. Model..

[34]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998 .

[35]  Burkhard Rost,et al.  Structural genomics is the largest contributor of novel structural leverage , 2009, Journal of Structural and Functional Genomics.

[36]  Z. Deng,et al.  Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors. , 2006, Journal of medicinal chemistry.

[37]  B. Shoichet,et al.  Flexible ligand docking using conformational ensembles , 1998, Protein science : a publication of the Protein Society.

[38]  Irwin D. Kuntz,et al.  Virtual Screening of Combinatorial Libraries across a Gene Family: in Search of Inhibitors of Giardia lamblia Guanine Phosphoribosyltransferase , 2001, Antimicrobial Agents and Chemotherapy.

[39]  Thierry Langer,et al.  Parallel Screening: A Novel Concept in Pharmacophore Modeling and Virtual Screening , 2006, J. Chem. Inf. Model..

[40]  D. J. Price,et al.  Assessing scoring functions for protein-ligand interactions. , 2004, Journal of medicinal chemistry.

[41]  Kalidas Yeturu,et al.  PocketMatch: A new algorithm to compare binding sites in protein structures , 2008, BMC Bioinformatics.

[42]  I. Kuntz,et al.  Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Didier Rognan,et al.  In silico-guided target identification of a scaffold-focused library: 1,3,5-triazepan-2,6-diones as novel phospholipase A2 inhibitors. , 2006, Journal of medicinal chemistry.

[44]  Somesh D. Sharma,et al.  Managing protein flexibility in docking and its applications. , 2009, Drug discovery today.

[45]  Gilles Marcou,et al.  Hot-Spots-Guided Receptor-Based Pharmacophores (HS-Pharm): A Knowledge-Based Approach to Identify Ligand-Anchoring Atoms in Protein Cavities and Prioritize Structure-Based Pharmacophores , 2008, J. Chem. Inf. Model..

[46]  Richard A. Lewis,et al.  Three-dimensional pharmacophore methods in drug discovery. , 2010, Journal of medicinal chemistry.

[47]  Jian Zhang,et al.  Peptide deformylase is a potential target for anti‐Helicobacter pylori drugs: Reverse docking, enzymatic assay, and X‐ray crystallography validation , 2006, Protein science : a publication of the Protein Society.

[48]  Gerhard Klebe,et al.  Relibase: design and development of a database for comprehensive analysis of protein-ligand interactions. , 2003, Journal of molecular biology.

[49]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[50]  Q. Do,et al.  Reverse Pharmacognosy: Application of Selnergy, a New Tool for Lead Discovery. The Example of ε-Viniferin , 2005 .

[51]  Thierry Langer,et al.  LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..

[52]  Hugo Kubinyi,et al.  Success Stories of Computer‐Aided Design , 2006 .

[53]  N. Gold,et al.  Fold independent structural comparisons of protein-ligand binding sites for exploring functional relationships. , 2006, Journal of molecular biology.

[54]  J. Irwin,et al.  Benchmarking sets for molecular docking. , 2006, Journal of medicinal chemistry.

[55]  Andreas Bender,et al.  Ligand-Target Prediction Using Winnow and Naive Bayesian Algorithms and the Implications of Overall Performance Statistics , 2008, J. Chem. Inf. Model..

[56]  Joannis Apostolakis,et al.  GlamDock: Development and Validation of a New Docking Tool on Several Thousand Protein-Ligand Complexes , 2007, J. Chem. Inf. Model..

[57]  Xiaomin Luo,et al.  TarFisDock: a web server for identifying drug targets with docking approach , 2006, Nucleic Acids Res..

[58]  L. Meijer,et al.  Inverse in silico screening for identification of kinase inhibitor targets. , 2007, Chemistry & biology.

[59]  Michael M. Mysinger,et al.  Automated Docking Screens: A Feasibility Study , 2009, Journal of medicinal chemistry.

[60]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[61]  Didier Rognan,et al.  Ranking Targets in Structure-Based Virtual Screening of Three-Dimensional Protein Libraries: Methods and Problems , 2008, J. Chem. Inf. Model..

[62]  D. Rognan Chemogenomic approaches to rational drug design , 2007, British journal of pharmacology.

[63]  Lin He,et al.  Harvesting Candidate Genes Responsible for Serious Adverse Drug Reactions from a Chemical-Protein Interactome , 2009, PLoS Comput. Biol..

[64]  I. Muegge,et al.  Virtual screening for kinase targets. , 2004, Current medicinal chemistry.

[65]  K. Kinoshita,et al.  Identification of protein functions from a molecular surface database, eF-site , 2004, Journal of Structural and Functional Genomics.

[66]  Renxiao Wang,et al.  The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. , 2004, Journal of medicinal chemistry.

[67]  Elaine C. Meng,et al.  Structure of a non-peptide inhibitor complexed with HIV-1 protease. Developing a cycle of structure-based drug design. , 1997 .

[68]  Thierry Langer,et al.  Pharmacophore modeling and parallel screening for PPAR ligands , 2007, J. Comput. Aided Mol. Des..

[69]  Pierre Acklin,et al.  Similarity Metrics for Ligands Reflecting the Similarity of the Target Proteins , 2003, J. Chem. Inf. Comput. Sci..

[70]  G. Schneider,et al.  Model structure of APOBEC3C reveals a binding pocket modulating ribonucleic acid interaction required for encapsidation , 2009, Proceedings of the National Academy of Sciences.

[71]  Meir Glick,et al.  Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases , 2006, J. Chem. Inf. Model..

[72]  E. Kellenberger,et al.  A simple and fuzzy method to align and compare druggable ligand‐binding sites , 2008, Proteins.

[73]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[74]  R. Abagyan,et al.  Pocketome via Comprehensive Identification and Classification of Ligand Binding Envelopes* , 2005, Molecular & Cellular Proteomics.

[75]  Thierry Langer,et al.  In silico Target Fishing for Rationalized Ligand Discovery Exemplified on Constituents of Ruta graveolens , 2008, Planta medica.

[76]  Nathanael Weill,et al.  Alignment-Free Ultra-High-Throughput Comparison of Druggable Protein-Ligand Binding Sites , 2010, J. Chem. Inf. Model..

[77]  C L Brooks,et al.  Ligand-protein database: linking protein-ligand complex structures to binding data. , 2001, Journal of medicinal chemistry.

[78]  Vladimir Poroikov,et al.  Robustness of Biological Activity Spectra Predicting by Computer Program PASS for Noncongeneric Sets of Chemical Compounds , 2000, J. Chem. Inf. Comput. Sci..

[79]  T. Klabunde Chemogenomic approaches to drug discovery: similar receptors bind similar ligands , 2007, British journal of pharmacology.

[80]  Luc Morin-Allory,et al.  Reverse pharmacognosy: identifying biological properties for plants by means of their molecule constituents: application to meranzin. , 2007, Planta medica.

[81]  Sean Ekins,et al.  Computer Applications in Pharmaceutical Research and Development , 2008 .

[82]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[83]  Haruki Nakamura,et al.  Remediation of the protein data bank archive , 2007, Nucleic Acids Res..

[84]  Malin M. Young,et al.  Design, docking, and evaluation of multiple libraries against multiple targets , 2001, Proteins.

[85]  J. Bajorath Computational analysis of ligand relationships within target families. , 2008, Current opinion in chemical biology.

[86]  N. Paul,et al.  Recovering the true targets of specific ligands by virtual screening of the protein data bank , 2004, Proteins.

[87]  B. Shoichet,et al.  Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes. , 2003, Journal of medicinal chemistry.

[88]  Thierry Langer,et al.  Parallel Screening and Activity Profiling with HIV Protease Inhibitor Pharmacophore Models , 2007, J. Chem. Inf. Model..

[89]  Didier Rognan,et al.  How to Measure the Similarity Between Protein Ligand-Binding Sites? , 2008 .

[90]  Jan M. Kriegl,et al.  Form follows function: Shape analysis of protein cavities for receptor‐based drug design , 2009, Proteomics.

[91]  Nathanael Weill,et al.  Development and Validation of a Novel Protein-Ligand Fingerprint To Mine Chemogenomic Space: Application to G Protein-Coupled Receptors and Their Ligands , 2009, J. Chem. Inf. Model..